PBM Accountability Project Statement on Trump Administration Efforts to Address High Prescription Drug Costs

President Trump this week signed an executive order that revived a drug pricing policy, known as the “most favored nation” policy, that failed to reduce prescription drug prices in his first term.

Mark Blum, managing director of the PBM Accountability Project, issued the following statement:

“The President’s ‘Most Favored Nation’ policy may aim to lower drug costs, but it misses the uniquely American reality – the most powerful and deliberately opaque driver of high drug costs: PBMs. These corporate middlemen, whom President Trump once vowed to ‘knock out,’ remain firmly entrenched, exploiting both public and private benefit programs and generating record profits while adding little value to patients. The executive order President Trump signed this week still fails to lay a glove on PBM middlemen.

“No other nation permits supply chain middlemen to operate with such impunity – or allows them to increase their revenues through offshore Group Purchasing Organizations acting as shadow profiteers. PBMs and their insurer-backed networks have mastered the art of profiteering behind closed doors, exploiting loopholes and siphoning billions from the system.

“Americans across the political spectrum are demanding action. Until policymakers confront predatory PBM pricing practices, no drug pricing reform – no matter how well-intentioned – will deliver real relief to American families. It’s time to finally deliver on the promise to reform the prescription drug supply chain, prioritize patients over profiteers and bring accountability to the middlemen who have gamed the system for too long.”

To learn more about the PBM issue and legislative solutions, click here.